a2 Milk Just Dropped 12% in a Day — But It's Still Up 32% This Year

A Wild Ride for NZ's Biggest Dairy Stock

The a2 Milk Company just had one of its worst single-day sell-offs in recent memory, plunging 12.4% to around $9.82 NZD in a session that wiped hundreds of millions off its market cap. For a stock that's been one of the NZX's strongest performers over the past twelve months — up roughly 32% year-on-year — it was a jarring reminder of how quickly sentiment can shift.

But here's the thing: even after that drop, a2 Milk is still trading well above its 52-week low of $7.80 and remains one of the most valuable companies on the New Zealand exchange, with a market cap north of $7 billion NZD.

What Spooked the Market?

The sell-off appears to be a classic case of a stock running too far, too fast. a2 Milk had been on a tear heading into April, climbing toward the upper end of its 52-week range of $7.80–$11.90. When you're trading at a P/E ratio of around 33x trailing earnings, there's not a lot of room for disappointment — and profit-taking can be brutal.

There's also the broader question of whether the China infant formula market, which drives the bulk of a2 Milk's revenue, can sustain its growth trajectory given China's declining birth rate. It's a concern that periodically rattles investors, even when the company's own numbers tell a different story.

The Numbers Tell a Strong Story

a2 Milk's recent financial performance has been genuinely impressive:

• •FY2025 revenue: NZ$1.90 billion, up 14% year-on-year
• •FY2026 guidance: Upgraded to "mid double-digit" revenue growth, up from "low double-digit" previously
• •NZ$2 billion revenue target: Now expected to be hit in FY2026, a full year ahead of the company's own amended plan
• •EPS (trailing): $0.17 NZD per half, with consensus forecasts of $0.30 for the full year
• •Market cap: ~$7.1 billion NZD

The guidance upgrade is the standout here. Management doesn't just think growth is continuing — they think it's accelerating. The company is now confidently targeting that NZ$2 billion revenue milestone, which seemed ambitious not long ago.

China Remains the Growth Engine

For all the hand-wringing about China's demographics, a2 Milk continues to gain market share in the Chinese infant formula market. The company's "China label" products — manufactured locally and sold through Chinese retail channels — have been a key growth driver, complementing the traditional cross-border "English label" business.

The strategy of having a dual-channel approach in China gives a2 Milk resilience that single-channel competitors lack. Even as the total addressable market for infant formula in China shrinks with fewer births, a2 Milk is taking a bigger slice of a still-enormous pie.

What the Analysts Think

The consensus analyst target sits at around $11.14 NZD, which is roughly where the stock was trading before the sell-off. That implies meaningful upside from current levels around $9.82 — approximately 13% to the consensus target.

The overall analyst recommendation is Hold, which in broker-speak typically means "we like it but it's fairly valued." After this pullback, some of those Hold ratings could shift to Buy if the price stays depressed.

What to Watch

• •FY2026 results (due August 2026): The market will want to see whether that upgraded guidance translates into actual numbers. Any miss would be punished harshly at this valuation.
• •China birth rate data: Every new data point on Chinese demographics gets scrutinised for what it means for formula demand.
• •Currency movements: a2 Milk earns in multiple currencies but reports in NZD. A weaker Kiwi dollar flatters reported earnings; a stronger one does the opposite.
• •Margin expansion: Revenue growth is great, but investors want to see profits growing even faster. Watch for operating margin trends.

The Bottom Line

a2 Milk's 12% single-day drop looks dramatic, but the underlying business is executing well — revenue is growing at double-digit rates, China sales are strong, and guidance has been upgraded. At around $9.82, you're buying a proven growth company at a meaningful discount to where it traded just days ago. The risk is that a P/E in the low 30s still prices in a lot of optimism, and any stumble in China would hurt. For investors with a 2-3 year horizon, this dip looks more like opportunity than danger signal.

*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*